Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism

Toxicology and Applied Pharmacology

Volumn 146, Issue 1, 1997, Pages 88-94

  Umbenhauer, Diane R ^a   Lankas, George R ^a   Pippert, Todd R ^a   Wise, L David ^a   Cartwright, Mark E ^a   Hall, Steven J ^a   Beare, Carolann M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ARTICLE; FEMALE; GENE EXPRESSION; INHERITANCE; MALE; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANIMALIA;

EID: 0030963724     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8225     Document Type: Article

References (28)

1. Arceci R. J., Croop J. M., Horwitz S. B., Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc. Natl. Acad. Sci. USA. 85:1988;4350-4354.
2. Barrand M. A., Twentyman P. R. Differential recognition ofmdrmdr. Br. J. Cancer. 65:1992;239-245.
3. Borst P., Schinkel A. H., Smit J. J. M., Wagenaar E., van Deemter L., Smith A. J., Eijdems E. W. H. M., Baas F., Zaman G. J. R. Classical and novel forms of multidrug resistance and the physiological functions of p-glycoproteins in mammals. Pharmac. Ther. 60:1993;289-299.
4. Borst P., Schinkel A. H. What have we learnt thus far from mice with disrupted p-glycoprotein genes? Euro. J. Cancer. 32:1996;985-990.
5. Buschman E., Arceci R. J., Croop J. M., Che M., Arias I. M., Housman D. E., Gros P. mdr2. J. Biol. Chem. 267:1992;18093-18099.
6. Croop J. M., Raymond M., Haber D., Devault A., Arceci R. J., Gros P., Housman D. E. The three mouse multidrug resistance (mdr. Mol. Cell. Biol. 9:1989;1346-1350.
7. Fisher M. H., Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 32:1992;537-553.
8. Georges E., Bradley G., Gariepy J., Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 87:1990;152-156.
9. Greenberger L. M., Croop J. M., Horwitz S. B., Arceci R. J. P-glycoproteins encoded bymdr. FEBS Lett. 257:1989;419-421.
10. Hogan B., Costantini F., Lacy E. Manipulating the Mouse Embryo. 1986;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
11. Hsu S.I-H, Cohen D., Kirschner L. S., Lothstein L., Hartstein M., Horwitz S. B. Structural analysis of the mousemdr. Mol. Cell. Biol. 10:1990;3596-3606.
12. Lankas G. R., Gordon L. R. Toxicology. Ivermectin and Abamectin. 1989;Springer-Verlag, Berlin/Heidelberg. p. 89-112.
13. Lankas G. R., Cartwright M. E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurototoxicity. Toxicol. Appl. Pharmacol. 143:1997;357-365.
14. Mayer U., Magenaar E., Beijnen J. H., Smit J. W., Meijer D. K. F., van Asperen J., Borst P., Schinkel A. H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1996;1038-1044.
15. MECTIZAN® Program Notes, One Copenhill, Atlanta, GA, USA.
16. Raymond M., Gros P. Mammalian multidrug-resistance gene: Correlation of exon organization with structural domains and duplication of an ancestral gene. Proc. Natl. Acad. Sci. USA. 86:1989;6488-6492.
17. Raymond M., Rose E., Housman D., Gros P. Physical mapping, amplification, and overexpression of the mousemdr. Mol. Cell. Biol. 10:1990;1642-1651.
18. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 316:1985;817-819.
19. Ruetz S., Gros P. Phosphatidylcholine translocase: A physiological role for themdr2. Cell. 77:1994;1071-1081.
20. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
21. Schinkel A. H., Smit J. J. M., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A. A. M., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P. J., Berns A. J. M., Borst P. Disruption of the mousemdr1a. Cell. 77:1994;491-502.
22. Schinkel A. H., Mol C. A. A. M., Wagenaar E., van Deemter L., Smit J. J. M., Borst P. Multidrug resistance and the role of p-glycoprotein knockout mice. Eur. J. Cancer. 31:1995a;1295-1298.
23. Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A. A. M., Borst P. mdr1a P-glycoprotein in mice affects tissue distribution and pharmacology of cyclosporin A, digoxin and dexamethasone. J. Clin. Invest. 96:1995b;1698-1705.
24. Schuetz E. G., Schinkel A. H., Relling M. V., Schuetz J. D. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA. 93:1996a;4001-4005.
25. Schuetz E. G., Beck W. T., Schuetz J. D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996b;311-318.
26. Smit J. J. M., Schinkel A. H., Oude Elferink R. P. J., Groen A. K., Wagenaar E., van Deemter L., Mol C. A. A. M., Ottenhoff R., van der Lugt N. M. T., van Roon M. A., van der Valk M. A., Offerhaus G. J. A., Berns A. J. M., Borst P. Homozygous disruption of the murinemdr. Cell. 75:1993;451-462.
27. Teeter L. D., Becker F. F., Chisari F. V., Li D., Kuo M. T. Overexpression of the multidrug resistance genemdr. Mol. Cell. Biol. 10:1990;5728-5735.
28. Wacher V. J., Wu C-Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcin. 13:1995;129-134.